对CDK4/6抑制剂治疗的现实世界数据分析-以患者为中心的单中心研究
Isabell Ge1,2,3,4, Kai Berner3,4,5, Marlene Mathis3,4
1Department of Gynecology and Obstetrics, University Hospital Basel, 4031 Basel, Switzerland.
Cancers
|May 11, 2024
概括
在现实世界中,CDK4/6抑制剂 (CDKis) 显示出不同的乳腺癌疗效. 孕激素受体状态,转移部位和治疗调整显著影响结果,指导个性化策略.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 由于患者应答的显著变化,CDK4/6抑制剂 (CDKis) 在乳腺癌中的实际有效性正在调查中.
- 了解影响治疗结果的因素对于优化患者护理至关重要.
研究的目的:
- 在临床试验之外,评估CDK4/6抑制剂 (CDKis) 在乳腺癌患者的实际疗效.
- 确定与治疗反应和失败相关的预后和预测标记.
主要方法:
- 一个单一中心的回顾性研究分析了2016年11月至2020年5月的数据.
- 评估了无进展生存期 (PFS),治疗时间失败 (TTF) 和治疗益处.
- 使用Kaplan-Meier和多变量回归分析来确定显著的预测因素.
主要成果:
- 在86名患者中,67.4%的患者经历了治疗失败,46.5%的患者由于进展而失败. 中位数PFS为12个月,TTF为8.5个月.
- 66.3%和48.8%的患者分别获得了短期和长期治疗的好处.
- 孕激素受体表达,多个转移部位,肝转移,不良事件和糖尿病是PFS和TTF的显著预测因素. 治疗修改预测的益处.治疗修改预测的益处.
结论:
- 量身定制的治疗策略对于优化现实世界乳腺癌管理结果至关重要.
- 孕激素受体表达,转移负担和治疗调整是患者对CDK抑制剂反应的关键因素.
- 对个性化治疗方法的进一步研究是有必要的.
相关概念视频
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
01:21Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K